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Summary A study has been made of the way in which the number of events available for analysis in a clinical
trial was dependent on the recruitment period, the maximum follow-up time on individual patients and the
length of time between the start of the trial and its analysis. The events considered were deaths, local
recurrences and late radiation effects on normal tissue in patients treated for cancer of the laryngo-pharynx by
two different fractionation regimes. The relationship is demonstrated between the number of events and the
95% confidence intervals that can be placed on differences between results in the two arms of the trial. It was
found, in this particular trial, that no significant improvement in precision was gained by following up patients
beyond 5 years or carrying out the analysis later than 2 years after the end of recruitment. The results are
discussed in the context of the initial design of clinical trials, particularly those in which the aim is to test
therapeutic equivalence.
The power of a clinical trial to detect differences in the time
to an event with a given level of statistical significance
depends on the number of events observed where an event
can be either death, recurrence, or some other 'failure' such
as a late radiation effect on normal tissue. In trials of cancer
treatment, this number depends on three time periods that
should ideally be specified in the initial trial design.
The first is the time during which patient accrual into the
trial takes place. This will be determined by the expected rate
of entry of patients and the total number that are needed for
the required power as given in tables such as those published
by Freedman (1982) and Machin and Campbell (1987). A
statement of this number is now accepted as an essential part
of the protocol of any clinical trial, but over-optimistic
estimates of rate of entry and/or a lessening of enthusiasm of
participating clinicians with time may result in the required
number not being reached.
The second time period that will influence the number of
events observed is the maximum length of follow-up of each
individual patient. This is a topic seldom discussed in trial
reports, perhaps because the general policy has been that
follow-up should be for 'as long as possible' or to a conven-
tional 5 or 10 years. However, detailed follow-up of patients
in a multicentre trial involves considerable effort and ex-
pense. 'Flagging' patients in the UK with the Office of
Population Censuses and Surveys (Peto et al., 1977) is a
cheap method of ensuring that all deaths are known, but is
of little use in following other end-points such as tumour
recurrence, which may occur long before death or indeed not
lead to death at all if a patient is cured by subsequent
treatment. Up-to-date information about these other events
can only be obtained from the patients' clinical records and
requires contact between the trials centre and the treating
clinician on a regular basis. Unnecessary extension of the
follow-up period should, therefore, be avoided as far as the
statistical considerations of the trial are concerned.
The third time needing specification is that at which the
results of the trial are to be analysed. While early interim
analyses may be advisable to monitor the treatment effects,
the use of any interim result to stop entry into the trial or to
trigger early publication must take into account the effect of
repeated analyses on apparent significance levels. This is a
topic that has been discussed by many authors, e.g. Armitage
et al. (1969), Haybittle (1971) and Pocock (1977). The first
definitive analysis of a trial should take place when the
number of events has reached that necessary for the required
power to be achieved. Most reports of clinical trials compar-
ing survival data do not explicitly state that such a criterion
has been used for determining the time of analysis, although
George and Desu (1974) have discussed how such a time can
be estimated.
We have recently studied the way in which events ac-
cumulated in a trial that began to be planned over 28 years
ago. Our results show how, if we had, at the time ofplanning
this trial, the requisite data concerning the time-course of
occurrence of significant events, we could have saved our-
selves and the trial participants considerable time and effort.
Unfortunately there was a lack of suitable retrospective data
on which to base such considerations and the trial design was
very much influenced by the clinical concepts then current.
Our experience may therefore be of value for others planning
clinical trials of cancer treatment.
Materials and methods
In 1962 the planning of a multicentre trial began under the
auspices of the British Institute of Radiology to compare two
radiotherapy regimes in the treatment of cancer of the laryn-
gopharynx. The two regimes differed in their fractionation
schedules. One employed five fractions per week (one each
weekday), which was common radiotherapy practice at that
time. The other used three fractions per week (on Monday,
Wednesday and Friday), which, provided any difference in its
therapeutic effect was clinically unimportant, would be
beneficial to the patient because of a reduced number of
attendances, and would be more economical in the use of
radiotherapy machines and associated staff. Because of the
known radiobiological effects of changing fractionation, the
total dose to patients treated with three fractions per week
was set at 11 or 13% less than that given to patients treated
with five fractions per week, for the longer or shorter
schedules respectively. Recruitment started in 1966.
The initial aim was to recruit about 900 patients, which
would have given a 90% power of detecting a difference of
about 10% in 5-year event-free rate, should such a difference
really exist. As will be discussed later, this could have been
too modest an ambition for a trial that was set up to show
that one regime (three fractions/week) was no worse in
therapeutic outcome than the other and could therefore be
preferred on non-therapeutic grounds. However, the number
of participating centres and their likely number of suitable
patients constrained the planned entry to what seemed
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reasonably achievable. In the event, entry to the trial was less
than anticipated in the first 3 years (Figure 1), built up to a
maximum in the sixth year, but decreased thereafter. It was
decided to terminate entry after 10 years when a total of 713
patients who satisfied the protocol had been randomised.
This decision was made partly because of the fall in the rate
of entry and also because an estimate of the increase in
power that would be achieved by continuing to recruit up to
the projected 900 suggested that the costs involved out-
weighed the minimal benefit that would be achieved.
Another decision made at the start of the trial was that
each patient should be followed up for a maximum of 10
years. This was because the incidence of late normal tissue
effects was of particular interest and it was thought, at the
time, that a substantial proportion of these effects might not
be identifiable until between 5 and 10 years.
Several interim analyses were made and reported, the last
of these being in the seventeenth year after the start of the
trial (Wiernik et al., 1982). The first three analyses were made
during the recruitment period and were comparatively sim-
ple. They showed no significant difference between the two
arms and gave no cause for considering stopping entry into
the trial. A final analysis has now been made and its results
are reported elsewhere (Wiernik et al., 1990). The differences
in overall survival and tumour-free rates were not statistically
significant at the 5% level. When adjusted for important
prognostic factors, the relative risks (three fractions/five frac-
tions) and 95% confidence intervals were 1.05 (0.87- 1.27)
and 1.14 (0.92-1.43) for deaths and local recurrences respec-
tively.
From the data file, the survival time and status of a patient
at a time earlier than that of the final analysis could easily be
assessed. If, for example, a patient had entered the trial 2
years after the beginning of recruitment and had died after a
survival time of 7 years, then he or she would be classed as
alive with a survival time of 4 years in an analysis made 6
years after the start of the trial. It has therefore been possible
to study the effect on the number of events available for
analysis in three separate situations: (1) The recruitment
period being reduced, but a 10-year maximum follow-up
being maintained on each patient. (2) The maximum follow-
up on each patient being reduced but a 10-year recruitment
period being maintained. (3) Analysis being made at earlier
times, but the recruitment period and the maximum follow-
up of individual patients being kept at 10 years.
In I and 2 it was assumed that the analyses were made at
the time when all patients in the trial had been followed up
for the prescribed time. The events of interest were death
(from any cause), local recurrence (including tumour per-
sistence) and the first recorded late effect in normal tissue.
The main aim of this trial was to test the therapeutic
equivalence of the two fractionation regimes and to establish
the range within which any possible difference might fall. The
narrower this range the more useful the result would be in
providing clinicians with evidence for or against treating with
a reduced number of fractions. The 95% confidence intervals
for the estimated log relative risk (see Appendix) were there-
fore calculated in each situation.
Results
Shortening the recruitment period would, of course, have
reduced the total number of patients in the trial and hence
the number of observed events and statistical power. This is
shown in Figure 2a, where the shape of the curves reflects the
pattern of recruitment (Figure 1). Increased recruitment time
leads to a corresponding increase in the number of events
available for the final analysis. The curve for local recur-
rences lies below that for deaths because a considerable
number of deaths were without record of local recurrence
and have been assumed to be either due to distant metastases
or to intercurrent disease other than cancer of the laryn-
gopharynx.
The effect of limiting the follow-up on individual patients
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Figure 1 Number of patients entering the trial in each year of
the recruitment period.
is shown in Figure 2b. It is apparent that very few local
recurrences or late effects occurred after the first 3 years
following treatment for primary cancer of the laryngo-
pharynx. The curve for deaths also rises more steeply in the
early years of follow-up.
The effect of earlier analysis time on the number of events
is shown in Figure 2c. The rise up to 10 years is mainly due
to the increasing number of patients recruited into the trial,
but after 10 years the curves become less steep and approach
plateaus. This is particularly noticeable for recurrences and
late effects.
The corresponding effects on the precision of the estimates
of relative risk are shown in Figure 3 (see Appendix). It can
be seen in Figure 3a that, although there was a large reduc-
tion in the 95% confidence limits as recruitment extended
over the first 7 years (resulting in from 251 to 343 events
depending on the end-point; Figure 2a), the rate of reduction
was very much slower thereafter. This is because of the
inverse dependence of the confidence interval on the square
root of the number of events, and will be a characteristic of
all trials. Thus, the penalty incurred by stopping our trial
short of its aimed total of 900 patients was small. With our
final figure of 428 deaths, the 95% confidence limits on the
log relative risk of death are± 0.19. If we had achieved our
original aim, these limits would have been reduced only a
little further to+±0.17.
Figure 3b shows that very little advantage was obtained by
following up patients for as long as 10 years. For deaths,
increasing the follow-up time from I to 5 years reduces the
confidence limits from± 0.34 to± 0.22, but the further re-
duction achieved by extension to 10 years is only 0.03. For
studying local tumour control and late effects, 2 years would
have been sufficient, since the curves for these two end-points
only fall by 0.01 between 2 and 10 years.
As far as analysis time was concerned (Figure 3c), waiting
unti'I 5 years after the end of recruitment (15 years after the
start of the trial) achieved a reduction in the confidence limits
on the log relative risk of death of 0.03, but waiting to the
end of the 20-year period achieved a further reduction of
only 0.01. For local recurrences and late effects, waiting the
last 10 years reduced the confidence limits by only 0.01 so
that a final analysis could well have been made soon after the
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Figure 3 Effect on 95% confidence limits on log relative risk of
varying: recruitment time a, follow-up time on individual patients
b, analysis time after start of trial c. * Deaths, O
local recurrences, A A late effects.
Discussion
The above results show that very little was gained by delay-
ing the final analysis until all patients had been followed up
for 10 years. Limiting the follow-up on individual patients to
5 years and carrying out a final analysis 12 years after the
start of the trial (even though not all patients would have
been followed up for 5 years) would have resulted in a
negligible loss of precision in estimating the relative risks of
local recurrence and late radiation effects. Even for mortality
the loss would have been small: 309 deaths recorded instead
for 428, leading to 95% confidence limits of ± 0.22 instead
of ± 0.19. The pattern of accumulating events was not for-
seen at the planning stage, as adequate retrospective data on
groups of similar patients and their response to treatment
were not available. In Figure 4, the curve for all local recur-
rences derived from our trial patients shows very clearly the
small number of recurrences occurring in the second quin-
quennium of follow-up. About a quarter of the total ob-
served deaths occurred after 5 years, but the effect of these in
reducing the confidence limits was small (Figure 3b). One
consideration influencing the original choice of 10-year fol-
low-up was to identify the time of onset of late radiation
damage to normal tissue if any occurred. Very few data on
this were available at the time of setting up the trial. The
curve now derived from our trial results (Figure 4) shows
that follow-up beyond 5 years can contribute little to the
comparison of late normal tissue effects between the two
arms of the trial. In only 4% of all patients showing these
late effects did the first indication occur between 5 and 10
years.
We can also see from this study that, although the trial
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Figure 4 Event-free curves for deaths (- *), local recur-
rences, (0 O) and late effects (A A) in the whole trial.
size was quite large by the standards current in 1966 and the
differences in the outcomes in the two arms of the trial were
not statistically significant at the 5% level, we are still left
with some uncertainty about whether a clinically important
difference might exist. The mortality relative risk (three
fractions/five fractions) of 1.05 with 95% confidence interval
of 0.87-1.27 may be interpreted in various ways. For exam-
ple, it means that there is about a 70% chance of there being
some difference in favour of five fractions per week and a
30% chance of there being some difference in favour of three
fractions per week.
Several authors (Makuch & Simon, 1978; Blackwelder,
1982; Rodary et al., 1989) have discussed the design and
analysis of clinical trials where the aim is to demonstrate
'equivalence' between treatments. They point out that, for
such trials, the usual test of the null hypothesis is inappro-
priate, since 'insufficient evidence to reject the null hypothesis
does not imply evidence to accept it' (Blackwelder, 1982).
The correct procedure when comparing a new therapy which
may be desirable on grounds other than those of tumour
control or cure (three fractions per week in our case) with a
standard therapy (five fractions per week) is to decide on the
minimum difference in tumour control or cure which, if it
existed in favour of the standard therapy, would be so
clinically important that the new therapy could not be
justified. This is then the hypothesis to be tested, and the
P-value to quote is the probability of the observed result
being consistent with the true difference being greater than or
equal to the chosen minimum difference. If P is sufficiently
small, we can reject the hypothesis and opt for the new
therapy simply because of its socio-economic advantages.
As stated earlier, the initial intention in our trial was to
enter enough patients to have a reasonable power (90%) of
detecting a 10% difference in event-free rates at a 5% level of
significance. We could therefore, as an example, choose 10%
as being the minimum difference referred to above and test
the hypothesis that the five fraction per week event-free rate
minus the three fraction per week rate is greater than or
equal to 10% at (say) 5 years. Since the event-free rates for
both deaths and local recurrences at 5 years are about 55%
(Figure 4), a difference of 10% in these rates between the two
arms of the trial implies a relative risk (three fractions per
week to five fractions per week) of about 1.35 (see Appen-
dix). Carrying out such a test for survival and tumour-free
rates results in P-values of 0.005 and 0.07 respectively. Thus
the evidence for the event-free rate not being more than 10%
lower using three fractions per week is strong in the case of
survival and suggestive, if not completely convincing, in the
case of being tumour-free.
When a new treatment may be preferable for socio-
economic reasons provided that its control or cure of the
tumour is no worse than that of a standard treatment, then
the all-important question is how much worse are we pre-
pared to tolerate and still consider the new treatment worth
adopting. The answer to that question is bound to be very
subjective and to vary from one clinician to another. The
10% difference in event-free rates used above is likely to be
at the upper end of the acceptable range. If, for example, a
lower value of 5% were to be chosen as the critical difference
in 5-year event-free rates, implying a relative risk of about
1.16 (see Appendix), then the corresponding P-values from
the test in our trial are 0.16 and 0.46 for survival and
tumour-free rates respectively. We do not therefore have
strong evidence for rejecting the hypothesis that the
difference between rates is at least 5% in favour of five
fractions per week.
Large numbers of patients are required in trials of ade-
quate power to test such differences. Using the formula given
by Makuch and Simon (1978), one may calculate that, with
713 patients and the critical difference set at 10%, the power
of our trial was the not unreasonable value of 85%. But, if
the hypothesis to be tested for rejection at the P = 0.05 level
were that the difference is greater than or equal to 5%, then
about 3,400 patients are required for the trial to have a
power of 90% (Makuch & Simon, 1978).
In summary, therefore, our experience emphasises the
need, when planning a trial of cancer treatment, to give
serious consideration first of all to the number of events
required in order to obtain sufficient power to detect the
percentage difference that will satisfy clinicians who will have
to base any change in their method of treatment on the trial
results. It is particularly important not to underestimate this
number in a trial where the aim is to test therapeutic
equivalence. Having decided on this number, then existing
data on the pattern of deaths and recurrences in the disease
should be used to determine the maximum follow-up time on
each patient and the time for definitive analysis. Little will be
gained by follow-up beyond the time when the event-free
curves are beginning to flatten out, since the few extra events
that will be recorded beyond this point contribute little to the
precision of the estimates of treatment differences. Our trial
has provided data on the pattern of deaths, local recurrences
and late effects on normal tissue following the treatment of
squamous cell carcinoma of the laryngopharynx, and these
data can now be used as a guide in the conduct of future
trials at this site. Had such data been available to us in 1962,
when planning the trial, then it is clear that, instead of
delaying our final definitive analysis until more than 20 years
after the first patient entered the trial, we could have
achieved an almost equivalent result 7-8 years earlier.
Appendix
Relative risk, log relative risk and difference in event-free rates
The relative risk, R, is the ratio of the hazard rate in one
group to that in the other group and is related to the log
relative risk, A, by the equation:
R = eA
The standard error of A is V- where V-l El' + E2'
(Haybittle & Freedman, 1979), E, and E2 being the expected
events on the null hypothesis in each arm of the trial. With
approximately equal numbers of patients in each arm and A
not very different from zero:
El=E2=E, and V-'=2E-'=4d-'
since d, the total number of events, equals El + E2 = 2E.
Thus V-1 = 2d-I and the 95% confidence interval on anCLINICAL TRIAL RECRUITMENT, FOLLOW-UP AND ANALYSIS 691
estimate of A is from A -2 x 1.96d-I to A + 2 x 1.96d-1,
i.e. the confidence limits are ± 3.92d-1.
If A is small, then R! 1 + A, so that a log relative risk of
0.20 corresponds to a relative risk of 1.20 (more accurately
1.22 if no approximation is made). Thus confidence limits
± x on the estimate of log relative risk as shown in Figure 3
correspond to very similar confidence limits on the relative
risk, when x is small. However, while the confidence interval
on the former is set symmetrically about the estimate, the
interval is not set symmetrically about the latter, and it is for
this reason that the confidence limits for A rather than for R
are plotted in Figure 3.
A relative risk can be translated into a difference in event-
free rates at a given time by using the equation:
P2 (pl)R
where PI and P2 are the event-free rates at that time in
groups 1 and 2 respectively and R is the relative risk, group 2
to group 1. The relationship does not depend on the form of
the event-free curve but only on the proportional hazards
Table I Relative risk (log relative risk) corresponding to differences
(%) in event-free rates
Difference (%)
PI-P2 25% 50% 75%
5 1.16 (0.15) 1.15 (0.14) 1.24 (0.21)
10 1.37 (0.31) 1.32 (0.28) 1.50 (0.40)
15 1.66 (0.51) 1.51 (0.42) 1.78 (0.57)
Forthe example in the text ofa 10% difference centred on 55%, i.e. a
difference between 60% and 50%, the relative risk is 1.357.
assumption, i.e. that R remains constant over the time
studied. For any given values of PI and R, P2 can be cal-
culated, and hence the difference, P1 - P2. Table I shows the
relative risks that would give rise to three values of these
differences, expressed as percentages, for three values of PI.
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